运动康复对急性脑梗死患者NLR、PLR的影响

目的对急性脑梗死患者进行运动康复治疗,观察其对患者血NLR、PLR的影响。方法选取2018年5月至2020年4月住院的急性脑梗死患者120例,随机分为对照组和观察组,每组各60例,两组入院后均给予抗血小板聚集、降血糖等治疗,对照组按神经内科给予常规治疗,观察组在生命体征平稳后给予康复运动治疗;两组在治疗前及治疗后4周,清晨空腹时采集外周静脉血行NLR、PLR测定,在治疗前及治疗后2、4周进行日常生活活动能力、运动功能评定。结果观察组治疗后4周NLR、PLR水平明显低于同期对照组(P0.05),且日常生活活动能力、运动功能评分明显高于同期对照组(P0.05)。结论早期运动康复治疗可降低NLR、PLR值,提高肢体运动功能及日常生活活动能力。     

NLR、血清胱抑素C及IL-6检测在冠心病患者中的应用价值

目的探讨NLR、CysC及IL-6联合检测在冠心病患者中的应用价值。方法选取本院在2016年6月～2018年6月住院的85例冠心病患者作为研究对象,选取同期40例健康人群作为对照组,对两组的血清中性粒细胞与淋巴细胞比值(NLR)、血清胱抑素C(CysC)、白细胞介素6(IL-6)水平进行分析测定,并对结果进行分析。同时测定患者总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)等生化指标,并对结果进行分析。结果冠心病患者的NLR、CysC、IL-6检测水平明显高于对照组,差异有统计学意义(P0.05)。在冠心病患者中又以急性心肌梗死的NLR、CysC及IL-6各项检测值最高,稳定型心绞痛(SAP)各项检测值相对最低,且三组间检测水平差异有统计学意义(P0.05)。结论 NLR、CysC、IL-6在冠心病尤其是急性心肌梗死中显著升高,可作为冠心病的评价指标之一。     

Involvement of caspase-4 in IL-1 beta production and pyroptosis in human macrophages during dengue virus infection

Caspase-4 physically interacts with caspase-1 and is believed to be a proinflammatory caspase that can induce the inflammatory form of programmed cell death (pyroptosis) and the release of mature interleukin (IL)-1β. However, the function of caspase-4 in dengue virus infection is not yet fully understood. We examined the function of caspase-4 in IL-1β production and pyroptosis during dengue virus serotype-2 (DENV-2) infection in human macrophages. In this study, DENV-2 infection increased IL-1β protein level with activated caspase-4 activity. Using primary macrophages, we observed that caspase-4 induces activation of caspase-1 and secretion of IL-1β in response to DENV-2 infection, without the need for secondary signals to stimulate the assembly of the inflammasome. These findings indicate that the regulation of caspase-1 activity by capsase-4 could represent a unique mechanism. Our data suggest that caspase-4 is upstream of caspase-1 in the pathway that regulates pyroptosis and IL-1β synthesis in macrophages during DENV-2 infection.     

Elevated pretreatment neutrophil-to-lymphocyte ratio indicate low survival rate in apatinib-treated patients with non-small cell lung cancer: A STROBE-compliant article

This study aimed to analyze the predictive value of the neutrophil-to-lymphocyte ratio (NLR) to better clarify which patients with advanced non-small cell lung cancer (NSCLC) would benefit most from apatinib after multiline treatment for drug resistance. This observational cohort study involved patients with advanced NSCLC who were treated with apatinib between May 2016 to May 2018. The participants in this study had previously been treated with at least two treatment regimens. Multivariate logistic regression and Cox proportional risk models were used to evaluate the overall survival (OS) and progression-free survival (PFS) of the pretreatment NLR. A total of 125 patients were reviewed. The median age was 64 years (range, 33–92); and 32.8% of the patients were female. Only 0.8% of the patients had an Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score ≥ 2. In multivariate analysis, pretreatment NLR ≥ 5 had an independent correlation with inferior OS (median 2.07 vs 3.40 months; HR 1.493, 95% CI 1.022–2.182; P = .038) and inferior PFS (median 1.83 vs 2.76 months; HR 1.478, 95% CI 1.015–2.153; P = .042). Elevated pretreatment NLR is associated with shorter OS and PFS in patients with advanced NSCLC treated with apatinib after multiline treatment for drug resistance.     

术前NLR PLR 与乳腺癌预后的相关性

目的：研究外周血中中性粒细胞和淋巴细胞绝对值的比值（neutrophil to lymphocyte ratio ,NLR ）、血小板和淋巴细胞绝对值的比值（platelet to lymphocyteratio ratio ,PLR ）与乳腺癌预后的相关性。方法：收集2011年1 月至2014年12月延边大学附属医院316 例行乳腺癌根治术患者的临床病理资料,分析NLR 、PLR 与乳腺癌TNM 分期、雌激素受体、HER-2 及三阴性乳腺癌之间的关系。结果：NLR 与乳腺癌TNM 分期之间有相关性（P < 0.05）、与乳腺癌雌激素受体、HER-2 及三阴性乳腺癌之间无相关性（P > 0.05）,PLR 与乳腺癌TNM 分期及雌激素受体、HER-2 及三阴性乳腺癌之间均无相关性（P > 0.05）。 结论：术前NLR 水平作为全身炎症反应的指标可有效预测乳腺癌的预后。     

Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer

Most patients with pancreatic cancer are ineligible for curative resection at diagnosis, resulting in poor prognosis. This study aimed to evaluate the prognostic factors in patients with unresectable pancreatic cancer.We retrospectively collected clinical data from 196 patients with unresectable pancreatic cancer who received palliative chemotherapy (N = 153) or palliative care alone (N = 43) from January 2011 to December 2013. Patients’ background data and overall survival were analyzed using the Cox proportional hazard regression model.In patients receiving palliative chemotherapy (gemcitabine-based regimen, 88.2%) and palliative care alone, the median (range) ages were 68 (43–91) and 78 (53–90) years, and metastatic diseases were present in 80% (N = 123) and 86% (N = 37), respectively. Multivariate analysis in the palliative chemotherapy patients showed that liver metastasis (hazard ratio [HR] 2.25, 95% confidence interval [CI] 1.58–3.20, P < .001), neutrophil-to-lymphocyte ratio (>4.5 vs ≤4.5; HR 3.45, 95% CI 2.22–5.36, P < .001), and cancer antigen 19-9 (CA19-9) (≥900 vs <900 U/mL; HR 1.45, 95% CI 1.02–2.05, P = .036) were independent prognostic factors. In those receiving palliative care alone, lung (HR 3.27, 95% Cl 1.46-7.35, p = 0.004) and peritoneum (HR 2.50, 95% CI 1.20–5.18, P = .014) metastases and the C-reactive protein-to-albumin ratio (≥1.3 vs <1.3; HR 3.33, 95% Cl 1.51–7.35, P = .003) were independent prognostic factors. Furthermore, patients with multiple factors had worse prognosis in both groups. Median survival time of palliative chemotherapy patients with risk factors 0, 1, 2, and 3 were 13.1 (95% CI 8.0–16.9), 9.4 (95% CI 7.9–10.1), 6.6 (95% CI 4.9–7.8), and 2.5 (95% CI 1.7–4.0) months, respectively. Similarly, median survival time was 5.7 (95% CI 1.3 -8.0), 2.1 (95% CI 1.5–3.9), and 1.3 (95% CI 0.6–1.7) months, respectively, for palliative care alone patients with risk factor 0, 1, and 2 to 3.Prognostic markers for pancreatic cancer were neutrophil-to-lymphocyte ratio, liver metastasis, and CA19-9 in patients undergoing palliative chemotherapy and C-reactive protein-to-albumin ratio and lung/peritoneum metastases in patients undergoing palliative care alone. These simple markers should be considered when explaining the prognosis and therapeutic options to patients.     

Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer

Background:

At least 30% of patients with primary resectable non-small cell lung cancer (NSCLC) will experience a relapse in their disease within 5 years following definitive treatment. Clinicopathological predictors have proved to be suboptimal in identifying high-risk patients. We aimed to establish whether inflammation-based scores offer an improved prognostic ability in terms of estimating overall (OS) and recurrence-free survival (RFS) in a cohort of operable, early-stage NSCLC patients.

Methods:

Clinicopathological, demographic and treatment data were collected prospectively for 220 patients operated for primary NSCLC at the Hammersmith Hospital from 2004 to 2011. Pretreatment modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were tested together with established prognostic factors in uni- and multivariate Cox regression analyses of OS and RFS.

Results:

Half of the patients were male, with a median age of 65. A total of 57% were classified as stage I with adenocarcinoma being the most prevalent subtype (60%). Univariate analyses of survival revealed stage (P<0.001), grade (P=0.02), lymphovascular (LVI, P=0.001), visceral pleural invasion (VPI, P=0.003), mGPS (P=0.02) and NLR (P=0.04) as predictors of OS, with stage (P<0.001), VPI (P=0.02) and NLR (P=0.002) being confirmed as independent prognostic factors on multivariate analyses. Patients with more advanced stage (P<0.001) and LVI (P=0.008) had significantly shorter RFS.

Conclusions:

An elevated NLR identifies operable NSCLC patients with a poor prognostic outlook and an OS difference of almost 2 years compared to those with a normal score at diagnosis. Our study validates the clinical utility of the NLR in early-stage NSCLC.